Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. (NASDAQ: AMGN) is a leading American multinational biopharmaceutical company, established in 1980 and headquartered in Thousand Oaks, California. As one of the largest independent biotechnology companies globally, Amgen specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise in advanced human genetics to develop solutions that dramatically improve people's lives.
Amgen's portfolio includes a range of flagship drugs such as red blood cell boosters Epogen and Aranesp, immune system enhancers Neupogen and Neulasta, and treatments for inflammatory diseases like Enbrel and Otezla. Additionally, the company has a strong presence in the oncology sector with products like Vectibix, Prolia, Evenity, and Kyprolis. Notably, the acquisition of Onyx Pharmaceuticals bolstered Amgen's oncology portfolio.
Recent launches include innovative therapies such as Repatha for cholesterol management, Aimovig for migraines, Lumakras for lung cancer, and Tezspire for asthma. In 2023, Amgen's acquisition of Horizon Therapeutics introduced several rare-disease drugs to its portfolio, including Tepezza for thyroid eye disease. Amgen also continues to expand its biosimilar portfolio, reinforcing its commitment to making advanced treatments more accessible.
Amgen's financial health is robust, with significant growth in revenues and product sales. The company's strategic partnerships and acquisitions have continually strengthened its market position. For instance, the recent Phase 3 SPROUT study demonstrated the efficacy and safety of Otezla in pediatric patients, highlighting Amgen's ongoing commitment to addressing various health needs. Furthermore, the company’s dedication to innovation is evident from its extensive pipeline of investigational drugs targeting various conditions.
Amgen has been acknowledged for its workplace culture and environmental initiatives, being named one of
Amgen will release its first quarter financial results on April 27, 2023, post market closure. The announcement will be followed by a conference call at 1:30 p.m. PT, featuring CEO Robert A. Bradway and senior management. Participants can access a live audio broadcast of the call, which will be available for replay for at least 90 days. Amgen, a leading biotechnology firm with a rich pipeline of medicines, was recognized in 2022 by Forbes as one of the "World's Best Employers" and by Barron's as one of "America's 100 Most Sustainable Companies." The company is part of both the Dow Jones Industrial Average and the Nasdaq-100 index.
Amgen announced that the U.S. Court of Appeals for the Federal Circuit upheld the validity of its patent for Otezla (apremilast), which is set to expire in February 2028. This ruling affirms a previous injunction preventing Sandoz and Zydus Pharmaceuticals from producing generic versions of Otezla during this period. The court validated U.S. Patent No. 7,427,638 and U.S. Patent No. 7,893,101 related to Otezla, while ruling against Amgen on U.S. Patent No. 10,092,541. Otezla is approved for treating plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's Disease.
Foresee Pharmaceuticals announced the appointment of Dr. Bassem Elmankabadi as Senior Vice President of Clinical Development on April 17, 2023. Dr. Elmankabadi brings over 17 years of clinical experience, previously holding leadership roles at Amgen (NASDAQ: AMGN) and FibroGen (NASDAQ: FGEN). His experience includes negotiating four Clinical Development Plans for Phase 2 and 3 studies for the company's drugs, Cudetaxestat and Pamrevlumab. Dr. Elmankabadi's background includes surgical leadership and clinical instruction at UCLA. Foresee Pharmaceuticals focuses on innovative therapies, with key products including CAMCEVI for advanced prostate cancer, approved in the U.S., Canada, and EU, as well as other promising candidates in clinical development.
Amgen (NASDAQ:AMGN) will present at the 2023 Oppenheimer Healthcare Conference on March 13, 2023, at 2:00 p.m. ET. Senior Vice President Susan Sweeney will represent the company. The presentation will be accessible through a live webcast for media, investors, and the public, with a replay available for 90 days post-event. Amgen focuses on developing innovative human therapeutics, using advanced genetics to address serious illnesses and unmet medical needs. A biotechnology leader since 1980, Amgen is a part of the Dow Jones Industrial Average and Nasdaq-100, recognized for its sustainability and employer ranking.
Amgen (NASDAQ:AMGN) declared a $2.13 per share dividend for Q2 2023, payable on June 8, 2023, to stockholders of record by May 18, 2023. This announcement highlights Amgen's commitment to returning value to shareholders while reflecting its strong market position. As a prominent player in biotechnology, Amgen's focus on innovative therapeutics aligns with its strategy of addressing high unmet medical needs. The company was recognized in 2022 for its commitment to sustainability and was named one of the 'World's Best Employers' by Forbes.
Amgen (NASDAQ:AMGN) will present at the 2023 TD Cowen Healthcare Conference on March 8, 2023, at 11:10 a.m. ET. The presentation will feature Murdo Gordon and Peter H. Griffith, executive vice presidents at Amgen. The event will be accessible via a live webcast for media, investors, and the public. Interested parties can find details on Amgen’s website under Investors, with the presentation archived for 90 days post-event. Amgen has been a pioneer in biotechnology since 1980, focusing on innovative therapies for serious illnesses and is recognized as one of the Dow Jones Industrial Average companies.
Amgen recently announced significant findings regarding its cholesterol-lowering therapies, Repatha (evolocumab) and olpasiran, at the American College of Cardiology's annual session (March 4-6, 2023, New Orleans). Data from the Phase 3 FOURIER and FOURIER-OLE studies showed that earlier and extended use of Repatha leads to a reduction in total cardiovascular events among patients with atherosclerotic cardiovascular disease (ASCVD). Furthermore, the Phase 2 OCEAN(a)-DOSE study demonstrated that olpasiran significantly reduces lipoprotein(a) levels regardless of baseline concentrations. Amgen also initiated the first LDL-C Action Summit to address challenges in cardiovascular care.
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
